1. Home
  2. MURA vs BOLD Comparison

MURA vs BOLD Comparison

Compare MURA & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MURA
    SELLHOLDBUYas of 2 days ago
  • BOLD
    SELLHOLDBUYas of 2024 years ago
  • Stock Information
  • Founded
  • MURA 2013
  • BOLD 2018
  • Country
  • MURA Ireland
  • BOLD United States
  • Employees
  • MURA N/A
  • BOLD N/A
  • Industry
  • MURA
  • BOLD
  • Sector
  • MURA
  • BOLD
  • Exchange
  • MURA Nasdaq
  • BOLD Nasdaq
  • Market Cap
  • MURA 57.2M
  • BOLD 54.9M
  • IPO Year
  • MURA N/A
  • BOLD 2024
  • Fundamental
  • Price
  • MURA $3.18
  • BOLD $2.59
  • Analyst Decision
  • MURA Strong Buy
  • BOLD Buy
  • Analyst Count
  • MURA 4
  • BOLD 3
  • Target Price
  • MURA $16.00
  • BOLD $22.50
  • AVG Volume (30 Days)
  • MURA 292.1K
  • BOLD 155.4K
  • Earning Date
  • MURA 11-13-2024
  • BOLD 11-07-2024
  • Dividend Yield
  • MURA N/A
  • BOLD N/A
  • EPS Growth
  • MURA N/A
  • BOLD N/A
  • EPS
  • MURA N/A
  • BOLD N/A
  • Revenue
  • MURA N/A
  • BOLD N/A
  • Revenue This Year
  • MURA N/A
  • BOLD N/A
  • Revenue Next Year
  • MURA N/A
  • BOLD N/A
  • P/E Ratio
  • MURA N/A
  • BOLD N/A
  • Revenue Growth
  • MURA N/A
  • BOLD N/A
  • 52 Week Low
  • MURA $2.87
  • BOLD $2.33
  • 52 Week High
  • MURA $6.25
  • BOLD $15.24
  • Technical
  • Relative Strength Index (RSI)
  • MURA 33.50
  • BOLD N/A
  • Support Level
  • MURA $2.87
  • BOLD N/A
  • Resistance Level
  • MURA $4.20
  • BOLD N/A
  • Average True Range (ATR)
  • MURA 0.28
  • BOLD 0.00
  • MACD
  • MURA -0.10
  • BOLD 0.00
  • Stochastic Oscillator
  • MURA 23.31
  • BOLD 0.00

Stock Price Comparison Chart: MURA vs BOLD

MURA
BOLD
December2024FebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember0246810121416MURA VS BOLD

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Share on Social Networks:

By browsing this website, you accept our Privacy Policy & Terms of Use